## Description:

**CARDIOVASCULAR AGENTS: LIPOTROPICS - ATP Citrate Lyase (ACL) Inhibitor**

<table>
<thead>
<tr>
<th>CLINICAL PA REQUIRED “PREFERRED”</th>
<th>PA REQUIRED “NON-PREFERRED”</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NEXLETOL™ (bempedoic acid)</td>
</tr>
<tr>
<td></td>
<td>NEXLIZET™ (bempedoic acid and ezetimibe tablet)</td>
</tr>
</tbody>
</table>

**CARDIOVASCULAR AGENTS: LIPOTROPICS – BILE ACID SEQUESTRANTS**

<table>
<thead>
<tr>
<th>NO PA REQUIRED “PREFERRED”</th>
<th>PA REQUIRED “NON-PREFERRED”</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHOLESTYRAMINE LIGHT POWDER (generic of Questran Light*)</td>
<td>COLESTIPOLO granules (generic of Colestid* granules)</td>
</tr>
<tr>
<td>CHOLESTYRAMINE POWDER (generic of Questran*)</td>
<td>WELCHOL® packets (colesevelam)</td>
</tr>
<tr>
<td>COLESTIPOLO tablets (generic of Colestid* tablets)</td>
<td>WELCHOL® tablets (colesevelam)</td>
</tr>
<tr>
<td>PREVALITE® POWDER (cholestyramine)</td>
<td></td>
</tr>
</tbody>
</table>

**CARDIOVASCULAR AGENTS: LIPOTROPICS - STATINS**

<table>
<thead>
<tr>
<th>NO PA REQUIRED “PREFERRED”</th>
<th>PA REQUIRED “NON-PREFERRED”</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATORVASTATIN (generic of Lipitor®)</td>
<td>ALTOPREV® (lovastatin)</td>
</tr>
<tr>
<td>LOVASTATIN (generic of Mevacor®)</td>
<td>EZALLOR™ SPRINKLE (rosuvastatin)</td>
</tr>
<tr>
<td>PRAVASTATIN (generic of Pravachol®)</td>
<td>FLUVASTATIN (generic of Lescol®, Lescol XL*)</td>
</tr>
<tr>
<td>ROSUVASTATIN (generic of Crestor*)</td>
<td>LIVALO® (pitavastatin)</td>
</tr>
<tr>
<td>SIMVASTATIN (generic of Zocor*)</td>
<td>ZYPITAMAG™ (pitavastatin)</td>
</tr>
</tbody>
</table>

**CARDIOVASCULAR AGENTS: LIPOTROPICS - FIBRIC ACID DERIVATIVES**

<table>
<thead>
<tr>
<th>NO PA REQUIRED “PREFERRED”</th>
<th>PA REQUIRED “NON-PREFERRED”</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEMFIBROZIL (generic of Lopid®)</td>
<td>ANTARA® (fenofibrate micronized capsules)</td>
</tr>
<tr>
<td>FENOFIBRATE TABLETS (generic of Tricor®)</td>
<td>FENOFIBRATE CAPSULES (generic of Lipofen*)</td>
</tr>
<tr>
<td></td>
<td>FENOFIBRIC ACID TABLETS (generic of Fibricor)</td>
</tr>
<tr>
<td></td>
<td>FENOFIBRIC ACID CAPSULES (generic of Trilipix*)</td>
</tr>
<tr>
<td></td>
<td>LOFIBRA® (fenofibrate micronized capsules)</td>
</tr>
<tr>
<td></td>
<td>TRIGLIDE® (fenofibrate tablets)</td>
</tr>
</tbody>
</table>

**CARDIOVASCULAR AGENTS: LIPOTROPICS - NICOTINIC ACID DERIVATIVES**

<table>
<thead>
<tr>
<th>NO PA REQUIRED “PREFERRED”</th>
<th>PA REQUIRED “NON-PREFERRED”</th>
</tr>
</thead>
</table>
## Cardiovascular Agents: Lipotropics

### Cardiovascular Agents: Lipotropics - Omega-3 Polyunsaturated Fatty Acids

<table>
<thead>
<tr>
<th>Clinical PA Required “Preferred”</th>
<th>PA Required “Non-Preferred”</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMEGA 3-ACID ETHYL ESTERS (generic of Lovaza®)</td>
<td>VASCEPA® (icosapent ethyl)</td>
</tr>
</tbody>
</table>

### Cardiovascular Agents: Lipotropics - Selective Cholesterol Absorption Inhibitors

<table>
<thead>
<tr>
<th>No PA Required “Preferred”</th>
<th>PA Required “Non-Preferred”</th>
</tr>
</thead>
<tbody>
<tr>
<td>EZETIMIBE (generic of ZETIA®)</td>
<td>SIMVASTATIN/EZETIMIBE (generic for Vytorin®)</td>
</tr>
</tbody>
</table>

### Cardiovascular Agents: Lipotropic/Hypertension Combination

<table>
<thead>
<tr>
<th>No PA Required “Preferred”</th>
<th>PA Required “Non-Preferred”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inability to utilize agents separately</td>
<td>AMLODIPINE/ATORVASTATIN (generic of Caduet®)</td>
</tr>
</tbody>
</table>

### Cardiovascular Agents: Lipotropics - PCSK9 Inhibitors*

<table>
<thead>
<tr>
<th>Clinical PA Required “Preferred”</th>
<th>PA Required “Non-Preferred”</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PRALUENT® (alirocumab)</td>
</tr>
<tr>
<td></td>
<td>REPATHA™ (evolocumab)</td>
</tr>
</tbody>
</table>

Note: Clinical criteria must be met

### FDA Approved Indication(s)

Lipotropic agents are indicated for the treatment of:
- angina
- atherosclerosis
- heterozygous familial hypercholesterolemia
- homozygous familial hypercholesterolemia
- hypercholesterolemia
- hyperlipoproteinemia
- hypertension
- hypertriglyceridemia
- myocardial infarction prophylaxis
- pruritus
- reduction of cardiovascular mortality
- stroke prophylaxis
- type 2 diabetes mellitus

### Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.
It is the policy of Buckeye Health Plan, an affiliate of Centene Corporation®, that Colestid granules, Welchol, Altoprev, Ezallor, Lescol, Lescol XL, Livalo, Zypitamag, Antara, Lipofen, Trilipix, Lofibra, Triglide, Niacin ER, Lovaza, Vascepa, Vytorin, Caduet, Praluent, and Repatha are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Bile Acid Sequestrants:
      1. FDA-approved or supported by standard pharmacopeias;
      2. Member must meet labeled age requirements for the medication;
      3. Dose does not exceed the FDA-approved maximum recommended dose for the relevant drug;
      4. Documentation that there has been a therapeutic failure to no less than a 30 day trial of at least one medication that is preferred and within the same class UNLESS there is a reason the member cannot be changed to a preferred medication. Acceptable reasons include:
         • Allergies to all medications not requiring prior approval.
         • Contraindication to or drug-to-drug interaction with medications not requiring prior approval.
         • History of unacceptable/toxic side effects to medications not requiring prior approval.
      5. For Welchol requests, may approve as first-line therapy if member meets one of the following (a or b):
         a. Documentation that the member has a diagnosis of diabetes;
         b. History of an oral hypoglycemic or insulin in the previous 120 days.
   Approval duration: 12 months.

   B. HMG-CoA Reductase Inhibitors (Statins) (must meet all):
      1. FDA-approved or supported by standard pharmacopeias;
      2. Member must meet labeled age requirements for the medication;
      3. Dose does not exceed the FDA-approved maximum recommended dose for the relevant drug;
      4. Documentation that there have been therapeutic failures to trials of no less than 30 days each of at least two medications that are preferred and within the same class UNLESS there is a reason the member cannot be changed to a preferred medication. Acceptable reasons include:
         • Allergies to all medications not requiring prior approval.
         • Contraindication to or drug-to-drug interaction with medications not requiring prior approval.
         NOTE: Pravastatin is the only HMG-CoA not metabolized by the cytochrome P450 liver enzyme system.
         • History of unacceptable/toxic side effects to medications not requiring prior approval.
   Approval duration: 12 months.

   C. Fibric Acid Derivatives (must meet all):
      1. FDA-approved or supported by standard pharmacopeias;
2. Member must meet labeled age requirements for the medication;
3. Dose does not exceed the FDA-approved maximum recommended dose for the relevant drug;
4. Documentation that there has been a therapeutic failure to no less than a 90 day trial of at least one medication that is preferred and within the same class UNLESS there is a reason the member cannot be changed to a preferred medication. Acceptable reasons include:
   • Allergies to all medications not requiring prior approval.
   • Contraindication to or drug-to-drug interaction with medications not requiring prior approval.
   • History of unacceptable/toxic side effects to medications not requiring prior approval.

Approval Duration: 12 months.

D. Nicotinic Acid Derivatives (must meet all):
1. FDA-approved or supported by standard pharmacopeias;
2. Member must meet labeled age requirements for the medication;
3. Dose does not exceed the FDA-approved maximum recommended dose for the relevant drug;
4. Documentation that there has been a therapeutic failure to no less than a 30 day trial of at least one medication that is preferred and within the same class UNLESS there is a reason the member cannot be changed to a preferred medication. Acceptable reasons include:
   a. Allergies to all medications not requiring prior approval.
   b. Contraindication to or drug-to-drug interaction with medications not requiring prior approval.
   c. History of unacceptable/toxic side effects to medications not requiring prior approval.

Approval Duration: 12 months.

E. Omega-3 Fatty Acids (must meet all):
1. Diagnosis of Hypertriglyceridemia;
2. Age ≥ 18 years;
3. Documentation that there has been a therapeutic failure to no less than a 30 day trial of at least one medication that is preferred and within the same class UNLESS there is a reason the member cannot be changed to a preferred medication. Acceptable reasons include:
   • Allergies to all medications that are preferred.
   • Contraindication to or drug-to-drug interaction with medications that are preferred.
   • History of unacceptable/toxic side effects to medications that are preferred.
4. Documentation that the member meets ALL of the following (a, b, AND c):
   a. Fasting triglycerides ≥ 500 mg/dL (lab must be dated within 90 days);
b. Member has been unable to lower triglyceride levels with fibrates, niacin, or lifestyle changes including diet and exercise;
c. Medications known to increase triglycerides (beta blockers, thiazides, and estrogens) have been discontinued or changed, if clinically appropriate.

5. Dose does not exceed 4 grams per day.

Approval Duration: 60 days.

F. Vytorin (Ezetimibe/Simvastatin) (must meet all):
1. Diagnosis of Hypercholesterolemia, Hyperlipoproteinemia, Homozygous Familial Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia, or Atherosclerotic Cardiovascular Disease;
2. Age ≥ 10 years;
3. Documentation that there has been a therapeutic failure to no less than a 30 day trial of at least one medication that is preferred and within the same class UNLESS there is a reason the member cannot be changed to a preferred medication. Acceptable reasons include:
   a. Allergies to all medications not requiring prior approval.
   b. Contraindication to or drug-to-drug interaction with medications not requiring prior approval.
   c. History of unacceptable/toxic side effects to medications not requiring prior approval.
4. Request does not exceed ezetimibe 10 mg/simvastatin 40 mg per day, or ezetimibe 10 mg/simvastatin 80 mg for member on previous therapy with simvastatin 80 mg for at least one year.

Approval Duration: 12 months.

G. Caduet (Amlodipine/Atorvastatin) (must meet all):
1. Diagnosis of one of the following (a, b, c, or d):
   a. Hypertension;
   b. Chronic stable angina;
   c. Confirmed or suspected vasospastic angina (Prinzmetal’s or Variant Angina);
   d. Coronary artery disease documented by angiography and without heart failure or an ejection fraction < 40%;
2. Diagnosis of coexisting hyperlipoproteinemia (hypercholesterolemia, type IV hypertriglyceridemia, or type III hyperlipoproteinemia);
3. Age ≥ 10 years;
4. Medical justification by physician for inability to use separate agents: atorvastatin and amlodipine;
5. Request does not exceed amlodipine 10 mg/atorvastatin 80 mg per day.

Approval Duration: 12 months.

H. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors (must meet ONE of the following [1, 2, OR 3]):
1. Diagnosis of Homozygous Familial Hypercholesterolemia (HoFH) and meets the following criteria:
   a. Request is for Repatha;
b. Prescribed by or in consultation with a cardiologist, endocrinologist or lipid specialist;
c. Age ≥ 13 years;
d. Documented adherence to prescribed lipid lowering medications for previous 90 days;

e. **Submission of baseline lipid laboratory results;**
f. Baseline untreated LDL-C levels of >500 mg/dL (>12.9 mmol/L) and treated levels ≥300 mg/dL (?7.7 mmol/L) AND TG within reference range or confirmation of diagnosis by gene or receptor testing;
g. Unable to reach goal LDL-C with maximally tolerated dose of statin plus ezetimibe (Zetia®) 10 mg daily with at least 1 other concurrently administered lipid lowering agent for **12 weeks**;
h. Dose of **Repatha** does not exceed 420 mg per month.

2. Diagnosis of **Heterozygous Familial Hypercholesterolemia (HeFH)** and meets the following criteria:
   a. Prescribed by or in consultation with a cardiologist, endocrinologist or lipid specialist;
   b. Age ≥ 18 years;
   c. Documented adherence to prescribed lipid lowering medications for previous 90 days;
   
   d. **Submission of baseline lipid laboratory results;**
   e. Baseline untreated LDL-C > 190 mg/dL and ONE of the following:
      • Presence of tendon xanthomas or 1st or 2nd degree relative with documented tendon xanthomas, MI at age < 60 years, or TC > 290 mg/dL OR
      • Confirmation of diagnosis by gene or receptor testing.
   f. Unable to reach goal LDL-C with maximally tolerated dose of statin for **12 weeks**. Must have a trial of TWO or more statins with at least one being atorvastatin.
   g. Dose of **Repatha** does not exceed 420 mg per month OR
   Dose of **Praluent** does not exceed 300 mg per month.

3. Diagnosis of **Clinical Atherosclerotic Cardiovascular Disease** and meets the following criteria:
   a. Prescribed by or in consultation with a cardiologist, endocrinologist or lipid specialist;
   b. Age ≥ 18 years;
   c. Documented adherence to prescribed lipid lowering medications for previous 90 days;
   
   d. **Submission of baseline lipid laboratory results;**
   e. History of MI, angina, coronary or other arterial revascularization, stroke, TIA or PVD of atherosclerotic origin;
   f. Unable to reach goal LDL-C with maximally tolerated dose of statin for **12 weeks**. Must have a trial of TWO or more statins with at least one being atorvastatin.
   g. Dose of **Repatha** does not exceed 420 mg per month OR
   Dose of **Praluent** does not exceed 300 mg per month.
Clinical Policy
Cardiovascular Agents: Lipotropics

Approval Duration: 84 days.

I. ATP Citrate Lyase (ACL) Inhibitors (must meet all):
   1. Age ≥18 years
   2. Documentation that there has been a therapeutic failure with one PCSK9 inhibitor
   3. Unable to reach goal LDL-C after a trial of 2 or more statins (one must be atorvastatin) at the maximally tolerated dose for 12 weeks
      a. If prescribed Nexlizet (bempedoic acid and ezetimibe tablet) approval requires the trial to be in combination with ezetimibe (Zetia) in addition to the above requirements
   4. Documented adherence to prescribed lipid lowering medications for previous 90 days. Baseline lab results are required, and approvals will be limited to 12 weeks initially and then annually thereafter. Subsequent approvals will require additional levels being done to assess changes
   5. Lipid profile required at week 8 for HeFH or ASCVD
   6. Diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH) and meets the following criteria:
      a. Total Cholesterol > 290mg/dl or LDL-C > 190 mg/dL and ONE of the following:
         • Presence of tendon xanthomas or 1st or 2nd degree relative with documented tendon xanthomas, MI at age ≤ 60 years, or TC > 290 mg/dL OR
         • Confirmation of diagnosis by gene or receptor testing.
   7. Diagnosis of Clinical Atherosclerotic Cardiovascular Disease and meets the following criteria:
      a. History of MI, angina, coronary or other arterial revascularization, stroke, TIA or PVD of atherosclerotic origin

Approval Duration: 84 days.

J. Other diagnoses/indications:
   1. There are no pharmacy and therapeutic committee approved off-label use criteria for the diagnosis;
   2. Use is supported by one of the following (a, b, or c):
      a. The National Comprehensive Cancer Network (NCCN) Drug Information and Biologics Compendium level of evidence 1 or 2A (see Appendix D);
      b. Evidence from at least two high-quality, published studies in reputable peer-reviewed journals or evidence-based clinical practice guidelines that provide all of the following (i – iv):
         i. Adequate representation of the member’s clinical characteristics, age, and diagnosis;
         ii. Adequate representation of the prescribed drug regimen;
         iii. Clinically meaningful outcomes as a result of the drug therapy in question;
         iv. Appropriate experimental design and method to address research questions (see Appendix E for additional information);
      c. Micromedex DrugDex® with strength of recommendation Class I, IIa, or IIb (see Appendix D);
   1. Prescribed by or in consultation with an appropriate specialist for the diagnosis;
   2. Failure of an adequate trial of at least two FDA-approved drugs for the indication and/or drugs that are considered the standard of care, when such agents exist for the
same indication at maximum indicated doses, unless no such drugs exist, at maximum indicated doses, unless contraindicated or clinically significant adverse effect are experienced;
3. Dosing regimen and duration are within dosing guidelines recommended by clinical practice guidelines and/or medical literature.

Approval duration: 12 months.

II. Continued Therapy
A. For Omega-3 Fatty Acids (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. Member is responding positively to therapy as evidenced by:
      a. Initial re-authorization: 20% reduction in TG levels from baseline;
      b. Subsequent re-authorizations: continued reduction or maintenance in reduction of TG levels from baseline;
   4. If request is for a dose increase, new dose does not exceed 4 g (4 capsules) per day.

Approval Duration: 12 months.

B. For Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. Member is responding positively to therapy as evidenced by lab results (a or b): a. Lipid profile required at week 8 for HeFH or ASCVD;
c. Lipid profile required after 3rd dose for HoFH.

Approval Duration: 12 months.

C. For ATP Citrate Lyase (ACL) Inhibitors (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. Member is responding positively to therapy as evidenced by lab results and lipid profile required at week 8 for HeFH or ASCVD

Approval Duration: 12 months.

III. Diagnoses/Indications for which coverage is NOT authorized:
Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents.

- Appendices/General Information
  Appendix A: Abbreviation/Acronym Key
  ASCVD: Atherosclerotic Cardiovascular Disease
  CHD: Coronary Heart Disease
  FDA: Food and Drug Administration
  FH: familial hypercholesterolemia
  HeFH: heterozygous familial hypercholesterolemia
  HoFH: homozygous familial hypercholesterolemia
  LDL-C: low density lipoprotein cholesterol
  LDLR: low density lipoprotein receptor
  LDLRAP1: low density lipoprotein receptor adaptor protein 1
  PCSK9: proprotein convertase subtilisin kexin 9
  SAMS: statin-associated muscle symptoms
  TIA: transient ischemic attack
  WHO: World Health Organization
  PA: Prior Authorization

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

**See above tables for preferred alternatives** Dosing varies by drug product. See FDA approved dosing and administration.

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings
- See package insert; clinical pharmacology or other appropriate clinical reference
V. Dosage and Administration: varies by drug product. See package insert; clinical pharmacology or other appropriate clinical reference for FDA approved dosing and administration.
VI. Product Availability: See package insert; clinical pharmacology or other appropriate clinical reference for product availability

VII. References. Refer to package insert.

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New policy created.</td>
<td>10.19</td>
<td>N/A</td>
</tr>
<tr>
<td>Updated non-preferred Fibric Acid Derivatives</td>
<td>03.20</td>
<td>N/A</td>
</tr>
<tr>
<td>Under Initial Approval criteria added section I. ATP Citrate Lyase (ACL) Inhibitors and Continued Therapy section C. For ATP Citrate Lyase (ACL) Inhibitors</td>
<td>07.20</td>
<td>N/A</td>
</tr>
<tr>
<td>Trial period for trial of preferred agents added 12 weeks for PCSK9 Inhibitors and 12 weeks for ATP Citrate Lyase (ACL) Inhibitors. Also under section I. ATP Citrate Lyase (ACL) Inhibitors added 2. Documentation that there has been a therapeutic failure with one PCSK9 inhibitor</td>
<td>11.20</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise
professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.
Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2019 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.